Back to Search Results
Image Place holder

Claudia Paba Prada, MD

 
Specialty: Hematology/Oncology
Program: Malignant Hematology and Cellular Therapy at Memorial Healthcare System

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Dr. Paba Prada earned her MD degree from Universidad Industrial de Santander in Bucaramanga, Colombia. She completed an Internal Medicine Residency at Pennsylvania Hospital, Philadelphia, and a Hematology/Oncology Fellowship at the University of Tennessee Health Science Center, Memphis. She then completed an Advanced Fellowship in Hematologic Malignancies at Dana Farber Cancer Institute, Boston. Following her fellowships, Dr. Paba Prada was an Attending Physician in the Department of Medical Oncology at Brigham and Women’s Hospital and a Clinical Physician in the Department of Hematologic Malignancies at Dana-Farber Cancer Institute. Prior to joining Moffitt, Dr. Paba Prada was a Clinical Physician in the Department of Hematologic Malignancies at Miami Cancer Institute. Dr. Paba Prada has a clinical interest in the management of plasma cell disorders, including monoclonal gammopathy of unknown significance, multiple myeloma, AL amyloidosis, POEMS syndrome and Waldenstrom macroglobulinemia. Her research focus is multiple myeloma.      


Education & Training

Fellowship:

  • Dana Farber Cancer Institute - Hematologic Malignancies
  • University of Tennessee Health Sciences Center - Hematology & Oncology

Residency:

  • Pennsylvania Hospital - Internal Medicine

Medical School:

  • Universidad Industrial de Santander - MD
Participating Trials

CLINICAL TRIAL 21249
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
Condition: Malignant Hematology
Intervention:
Open (affiliates only)

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Rowinsky EK, Paner A, Berdeja JG, Paba-Prada C, Venugopal P, Porkka K, Gullbo J, Linder S, Loskog A, Richardson PG, Landgren O. Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma. Invest New Drugs. 2020 Oct.38(5):1448-1453. Pubmedid: 32125598. Pmcid: PMC7497669.
  • Richardson PG, Bringhen S, Voorhees P, Plesner T, Mellqvist UH, Reeves B, Paba-Prada C, Zubair H, Byrne C, Chauhan D, Anderson K, Nordström E, Harmenberg J, Palumbo A, Sonneveld P. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. Lancet Haematol. 2020 May.7(5):e395-e407. Pubmedid: 32213344.
  • Ghobrial IM, Liu CJ, Zavidij O, Azab AK, Baz R, Laubach JP, Mishima Y, Armand P, Munshi NC, Basile F, Constantine M, Vredenburgh J, Boruchov A, Crilley P, Henrick PM, Hornburg KTV, Leblebjian H, Chuma S, Reyes K, Noonan K, Warren D, Schlossman R, Paba-Prada C, Anderson KC, Weller E, Trippa L, Shain K, Richardson PG. Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Am J Hematol. 2019 Nov.94(11):1244-1253. Pubmedid: 31456261.
  • Hari P, Paba-Prada CE, Voorhees PM, Frye J, Chang YL, Moreau P, Zonder J, Boccia R, Shain KH. Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Leuk Res. 2019 Aug.83:106172. Pubmedid: 31229804. Pmcid: PMC6871647.
  • O'Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG, Wade PM, Paba-Prada CE, Ghobrial IM, Schlossman RL, Burke JN, Harrington CC, Lively KJ, Lyons HF, Munshi NC, Anderson KC, Trippa L, Richardson PG, Raje NS. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Brit J Haematol. 2018 Jul.182(2):222-230. Pubmedid: 29740809. Pmcid: PMC6074026.
  • Lee N, Lockwood SJ, Richardson P, Paba-Prada C, Saavedra AP. IgA multiple myeloma in a patient with an IgG pemphigus foliaceus-like exanthem. Int J Dermatol. 2017 Oct.56(10):1058-1060. Pubmedid: 28856664.
  • Laubach JP, Paba Prada CE, Richardson PG, Longo DL. Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma. Clin Pharmacol Ther. 2017 Jan.101(1):81-88. Pubmedid: 27806428.
  • Richardson PG, Kumar S, Laubach JP, Paba-Prada C, Gupta N, Berg D, van de Velde H, Moreau P. New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib. J Blood Med. 2017 Aug.8:107-121. Pubmedid: 28860887. Pmcid: PMC5573039.
  • Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM, Gozzetti A, Gustine JN, Hajek R, Hungria V, Jarkovsky J, Jayabalan D, Laubach JP, Lewicka B, Maisnar V, Manasanch EE, Moreau P, Morgan EA, Nahi H, Niesvizky R, Paba-Prada C, Pika T, Pour L, Reagan JL, Richardson PG, Shah J, Spicka I, Vij R, Waszczuk-Gajda A, Gertz MA. IgM myeloma: A multicenter retrospective study of 134 patients. Am J Hematol. 2017 Aug.92(8):746-751. Pubmedid: 28383205.
  • Neri P, Bahlis NJ, Paba-Prada C, Richardson P. Treatment of Relapsed/Refractory Multiple Myeloma. Cancer Treat Res. 2016 Oct.169:169-194. Pubmedid: 27696263.
  • Jurczyszyn A, Olszewska-Szopa M, Vesole AS, Vesole DH, Siegel DS, Richardson PG, Paba-Prada C, Callander NS, Huras H, Skotnicki AB. Multiple Myeloma in Pregnancy--A Review of the Literature and a Case Series. Clin Lymphoma Myeloma Leuk. 2016 Mar.16(3):e39-e45. Pubmedid: 26847816.
  • Leblebjian H, Noonan K, Paba-Prada C, Treon SP, Castillo JJ, Ghobrial IM. Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia. Am J Hematol. 2015 Jun.90(6):E122-E123. Pubmedid: 25703132.
  • Varga C, Xie W, Laubach J, Ghobrial IM, O'Donnell EK, Weinstock M, Paba-Prada C, Warren D, Maglio ME, Schlossman R, Munshi NC, Raje N, Weller E, Anderson KC, Mitsiades CS, Richardson PG. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Brit J Haematol. 2015 Jun.169(6):843-850. Pubmedid: 26032514.
  • Weinstock M, Aljawai Y, Morgan EA, Laubach J, Gannon M, Roccaro AM, Varga C, Mitsiades CS, Paba-Prada C, Schlossman R, Munshi N, Anderson KC, Richardson PP, Weller E, Ghobrial IM. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Brit J Haematol. 2015 Jun.169(6):851-858. Pubmedid: 25833301. Pmcid: PMC5944324.
  • Banwait R, Aljawai Y, Cappuccio J, McDiarmid S, Morgan EA, Leblebjian H, Roccaro AM, Laubach J, Castillo JJ, Paba-Prada C, Treon S, Redd R, Weller E, Ghobrial IM. Extramedullary Waldenström macroglobulinemia. Am J Hematol. 2015 Feb.90(2):100-104. Pubmedid: 25349134.
  • Rosenbaum C, Jasielec J, Laubach J, Paba Prada C, Richardson P, Jakubowiak AJ. Evolving strategies in the initial treatment of multiple myeloma. Semin Oncol. 2013 Oct.40(5):592-601. Pubmedid: 24135404.
  • Chauhan D, Ray A, Viktorsson K, Spira J, Paba-Prada C, Munshi N, Richardson P, Lewensohn R, Anderson KC. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res. 2013 Jun.19(11):3019-3031. Pubmedid: 23584492. Pmcid: PMC4098702.
  • Richardson PG, Laubach J, Paba-Prada C, Anderson KC. IgD and IgE variants of myeloma: valuable insights and therapeutic opportunities. Oncology (Williston Park). 2013 Aug.27(8):803-4, 806. Pubmedid: 24133830.

Patient Comments
Overall Satisfaction
0
★★★★★
★★★★★

0 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments